Dihematoporphyrin Ether (Porfimer Sodium)

The purified component of HEMATOPORPHYRIN DERIVATIVE, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (HEMATOPORPHYRIN PHOTORADIATION); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of PHOTODYNAMIC THERAPY in the United States.

Also Known As:

Networked: 718 relevant articles (59 outcomes, 106 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Busch, Theresa M: 18 articles (08/2020 - 12/2002)
2.	Korbelik, Mladen: 14 articles (09/2013 - 09/2002)
3.	Zhu, Timothy C: 12 articles (01/2022 - 01/2005)
4.	Glatstein, Eli: 10 articles (01/2017 - 12/2002)
5.	Wolfsen, Herbert C: 9 articles (01/2010 - 02/2002)
6.	Cecic, Ivana: 9 articles (10/2008 - 09/2002)
7.	Hahn, Stephen M: 8 articles (01/2009 - 04/2003)
8.	Ikeda, Norihiko: 7 articles (12/2017 - 10/2008)
9.	Kulbacka, Julita: 6 articles (10/2018 - 01/2007)
10.	Ohtani, Keishi: 6 articles (12/2017 - 10/2008)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "However, porfimer sodium was more effective in treating NSCLC tumors to a depth of 6-10 mm. " 01/17/1996 - "In comparison, Photofrin required 8.4 mumol/kg for local tumor remission in 5 of 6 animals with 24 hr accumulation time after injection. " 01/01/1993 - "Animals treated with photofrin II had a 1 month cancer-free survival of 27% while animals treated with BPD had an improved survival of 67% (P = 0.03). " 09/15/2006 - "A secondary aim of this trial and the subject of this report is to determine Photofrin uptake in tumor and normal tissues. " 01/01/2004 - "A study was designed to determine the pharmacokinetic profile and variability of porfimer sodium in dogs and cats with spontaneous tumors and to thereby determine the optimal timing of its photoactivation in these species. "
2.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 06/01/1997 - "From this study, we conclude that photo-detection with Photofrin has potential in distinguishing chemically induced premalignant lesions and squamous cell carcinomas from the normal rat palatal mucosa. " 03/01/1995 - "Cellular populations in the squamous cell carcinoma SCCVII, growing in C3H/HeN mice given Photofrin, were examined at various time intervals during the photodynamic light treatment and up to 8 h later. " 06/01/1995 - "Studies on the pharmacokinetics of the fluorescent fraction of Photofrin in patients with early squamous cell carcinoma in the oral cavity, esophagus or bronchi show a signal contrast ranging from 1.5 to 3.5 a short time after intravenous injection that rapidly decreases and tends to unity (one) about 12 hours later. " 03/01/2003 - "Subcellular localization of Photofrin determines the death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic therapy: when plasma membranes are the main targets." 03/01/1998 - "Photodynamic therapy for facial squamous cell carcinoma in cats using Photofrin."
3.	Lung Neoplasms (Lung Cancer) 01/01/2021 - "The effectiveness of PS785 was compared with porfimer sodium in the treatment of human lung cancer xenografts in mice. " 02/01/1990 - "Detection of early lung cancer using low dose Photofrin II." 10/01/1993 - "A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. " 01/01/1996 - "Photodynamic therapy of lung cancer with bronchial artery infusion of photofrin." 03/17/1993 - "Phase III trials in esophageal cancer and lung cancer are in progress and will help in evaluation of whether Photofrin II, the most widely used sensitizer, can be added to the oncologic armamentarium, pending approval from the U.S. "
4.	Carcinoma (Carcinomatosis) 05/15/2019 - "Treatment of cervix carcinoma FIGO IIIb with Photofrin II as a radiosensitizer: a case report." 10/01/2000 - "The sonodynamically induced antitumor effect of Photofrin II (PF), was evaluated in mice bearing colon 26 carcinoma. " 10/01/2000 - "Sonodynamically induced antitumor effect of Photofrin II on colon 26 carcinoma." 04/01/1996 - "Patient treatment--A 70-year-old woman with recurrent local rectal carcinoma received intravenous Photofrin II (2 mg/kg). " 11/15/1993 - "The technique was applied in the developmental stages of the 9,10 dimethyl-1,2-benzanthracene (DMBA)-induced hamster buccal cheek pouch carcinoma model to (1) quantitate and characterize porfimer sodium fluorescence and uptake as it relates to lesion progression and biochemical changes and (2) determine whether porfimer sodium-induced fluorescence will vary with promotional and inhibitory stimuli. "
5.	Squamous Cell Carcinoma of Head and Neck 03/01/2020 - "Photofrin-mediated photodynamic therapy is useful for treating head and neck squamous cell carcinomas, and provides an improved quality of life in patients with recurrent or residual disease." 03/01/2020 - "Forty-two head and neck squamous cell carcinoma patients who underwent Photofrin-mediated photodynamic therapy were treated by intraoperative light activation at 630 nm via a fiber optic microlens, 48 h after injection. " 03/01/2020 - "Porfimer sodium-mediated photodynamic therapy in patients with head and neck squamous cell carcinoma." 09/01/2013 - "Treatment outcome of Photofrin-based photodynamic therapy for T1 and T2 oral squamous cell carcinoma and dysplasia." 01/01/2018 - "Thirty-three patients with HNSCC were treated with porfimer sodium-mediated PDT followed by intraoperative light activation at 630 nm via fiber optic microlens delivered after 48 hours of injection. "

Related Drugs and Biologics

1.	1-phenyl-3,3-dimethyltriazene (PDT)
2.	Photosensitizing Agents (Photosensitizers)
3.	Dihematoporphyrin Ether (Porfimer Sodium)
4.	Hematoporphyrin Derivative
5.	temoporfin
6.	Porphyrins
7.	Talaporfin (talaporfin sodium)
8.	Verteporfin (Visudyne)
9.	Singlet Oxygen
10.	chlorin

Related Therapies and Procedures

1.	Photochemotherapy (Photodynamic Therapy)
2.	Lasers (Laser)
3.	Drug Therapy (Chemotherapy)
4.	Stents
5.	Dye Lasers